CymaBay Therapeutics Announces Presentations During The International Liver Congress 2022

NEWARK, Calif. – CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced that multiple seladelpar presentations will be delivered during The International Liver Congress 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd – 26th .

Read the source article at Stock Market Quotes and News
2022-06-09 13:08:40